Related Experiment Video

Updated: May 18, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J Fermann1, Christopher J Lindsell, Alan B Storrow

  • 1Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH 34267-0769, USA. gregory.fermann@uc.edu

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|September 25, 2012
PubMed

Insights

Galectin 3 (G3) does not predict prognosis in acute heart failure. However, G3 combined with B-type natriuretic peptide may indicate kidney issues and predict short-term adverse events.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Galectin 3 (G3) is implicated in cardiac fibrosis and remodeling processes.
  • Understanding the role of G3 in heart failure is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the prognostic value of Galectin 3 (G3) in patients with Acute Heart Failure Syndromes (AHFS).
  • To assess the association of G3 with renal dysfunction and short-term adverse events in AHFS patients.

Main Methods:

  • Prospective enrollment of patients diagnosed with and treated for Acute Heart Failure Syndromes.
  • Inclusion in the multicenter Decision Making in Acute Decompensated Heart Failure trial.
  • Analysis of Galectin 3 levels in relation to clinical characteristics and outcomes.

Main Results:

  • Higher G3 levels were associated with a history of renal disease, acute kidney injury, and lower heart rate.
  • Patients with elevated G3 showed a tendency towards a history of heart failure (HF) and increased 30-day adverse events.
  • Comparison with B-type natriuretic peptide was performed to evaluate complementary roles.

Conclusions:

  • Galectin 3 (G3) alone does not offer prognostic value in Acute Heart Failure Syndromes.
  • G3, when used alongside B-type natriuretic peptide, is linked to renal dysfunction.
  • G3 may serve as a predictor for 30-day adverse events in heart failure patients.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...